about
Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?The antioxidant role of thiocyanate in the pathogenesis of cystic fibrosis and other inflammation-related diseasesThe Role of Oxygen Sensors, Hydroxylases, and HIF in Cardiac Function and DiseasePharmacology and Clinical Drug Candidates in Redox MedicineReactive oxygen species-activated nanomaterials as theranostic agents2-Thioxanthines Are Mechanism-based Inactivators of Myeloperoxidase That Block Oxidative Stress during InflammationModified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic ToxinsMyeloperoxidase: a front-line defender against phagocytosed microorganismsShort-Term Exposure to Air Pollution and Biomarkers of Oxidative Stress: The Framingham Heart StudyHealth risk assessment for air pollutants: alterations in lung and cardiac gene expression in mice exposed to Milano winter fine particulate matter (PM2.5)Melatonin prevents myeloperoxidase heme destruction and the generation of free iron mediated by self-generated hypochlorous acidEndothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals.In vivo administration of BL-3050: highly stable engineered PON1-HDL complexesMonocytes and neutrophils expressing myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques.Myeloperoxidase in human intracranial aneurysms: preliminary evidence.Novel biomarkers for cardiovascular risk prediction.Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasoundConcurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography--the LURIC study.Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjectsInhibition of myeloperoxidase-mediated hypochlorous acid production by nitroxidesPotential role of tryptophan and chloride in the inhibition of human myeloperoxidase.Myeloperoxidase polymorphism and coronary artery disease risk: A meta-analysis.Targeted probes for cardiovascular MRIMyeloperoxidase levels predicts angiographic severity of coronary artery disease in patients with chronic stable angina.Vasculitis: molecular imaging by targeting the inflammatory enzyme myeloperoxidase.Blueberries decrease cardiovascular risk factors in obese men and women with metabolic syndrome.Prediction of short-term clinical outcome of percutaneous coronary intervention in patients with acute coronary syndrome through myeloperoxidase levels.Atorvastatin protects against cerebral ischemia/reperfusion injury through anti-inflammatory and antioxidant effectsAltered inflammatory, oxidative, and metabolic responses to exercise in pediatric obesity and type 1 diabetes.The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings.Oxidative status imbalance in patients with metabolic syndrome: role of the myeloperoxidase/hydrogen peroxide axis.{Omega}-oxidation of {alpha}-chlorinated fatty acids: identification of {alpha}-chlorinated dicarboxylic acids.A synthetic polypeptide conjugate from a 42-residue polypeptide and salicylhydroxamic acid binds human myeloperoxidase with high affinity.Comprehensive peroxidase-based hematologic profiling for the prediction of 1-year myocardial infarction and death.Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease.Role of biomarkers in risk stratification of acute coronary syndromeMyeloperoxidase gene-463G > A polymorphism and premature coronary artery disease.Association of monocyte tumor necrosis factor α expression and serum inflammatory biomarkers with walking impairment in peripheral artery disease.Urate as a physiological substrate for myeloperoxidase: implications for hyperuricemia and inflammation
P2860
Q24630160-3169072D-3CA5-499B-B4F8-326AA4A1FF38Q24655891-789CC47D-8E8E-49F1-8425-80D7D88BCC0DQ26780548-D967A9D5-6A8F-4031-9532-FBC08E61D565Q26785525-89B6FDFE-C794-4413-82D2-F27E1EEF534AQ26865564-E05023A8-E093-46A9-B3AF-78BA5A37973AQ27672618-AC195074-74A6-4B3D-AF9C-71C822093E7EQ28074264-A1AD77E8-B587-4391-81F3-BBC9FFBB9190Q28393101-628739B9-0B3B-4FC6-B294-74BA01A7BB8DQ28395707-D12263C2-80B4-4541-B969-069E9136231BQ28543631-78DAA125-919D-4A31-AB51-909C4CA8EE26Q28545738-DFEBB372-0BD6-4197-8260-5776AB4424BEQ30492179-28A675E9-A6F1-4F4C-9F8E-E239B763A7EEQ30891417-E418C493-99F7-4DF2-B57F-06292DB5BF2CQ33473042-BF4AE2BC-8A8E-427D-8900-A7CABD38356DQ33611251-D6B51E14-B1FE-45EB-B932-6733CB7CCA0BQ33615459-CF239416-2BF2-4521-AD74-1B5F3DF08853Q33688005-74E13337-69A7-45F5-BF4E-D007A6DF993CQ33691730-A03EBDD9-1CDF-4229-A04F-9FD43BDBCA7EQ33709886-8B326074-7B23-4163-9CF7-B07631394303Q33723943-6A6A905E-A019-4054-B8AE-3660FDC56F3AQ33759336-F58C7C07-36F7-44DF-9DC6-6F09EFF878EEQ33818264-DF0430A0-3C87-46E3-83A4-6B6AA419EC34Q33885758-40B825F7-7034-4E12-B9E4-3BCD86F7313BQ33901726-33213845-409A-4284-880E-24C0227BEE78Q34072878-B0825536-B69F-4E5C-8329-15697F78D3CFQ34074677-EA6690AB-8D94-4AFB-B43C-9134228182E7Q34076088-CEC60791-DCE5-4BA6-8243-E151AAA52C01Q34088233-0CE4F900-69FF-4E5D-AA3F-A1D2DED683B6Q34095633-A3B47109-7AAF-4DB7-B0CE-D7E66EC0098CQ34153905-CCB58A81-3862-4F93-8808-25EF88924391Q34347558-1B8C94BF-94F6-4D95-87F7-96A6BCFE05A0Q34438220-3D09EFBF-5C7C-4B5F-9570-4A588CA9D867Q34438686-9D18BBEB-6B46-4767-AABC-FE641D3185E0Q34453789-0BE6A607-EC93-4907-9572-65576CB383FFQ34460042-6A359B0E-6DB5-4EFC-9059-D0A0690BB097Q34460370-09FBA428-3DD5-407B-9EEF-5619F5BB4B97Q34530136-D977F8F8-800E-47A7-A2C9-C23E25FFD7AAQ34565544-FC50FF20-C56F-4D29-A89C-FAD6372240B6Q34772426-9EDEABCF-792E-4446-83B6-77DF4B4F817AQ34787028-749C7891-E374-42BB-8F8F-73E7187988DA
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Myeloperoxidase and cardiovascular disease.
@ast
Myeloperoxidase and cardiovascular disease.
@en
Myeloperoxidase and cardiovascular disease.
@nl
type
label
Myeloperoxidase and cardiovascular disease.
@ast
Myeloperoxidase and cardiovascular disease.
@en
Myeloperoxidase and cardiovascular disease.
@nl
prefLabel
Myeloperoxidase and cardiovascular disease.
@ast
Myeloperoxidase and cardiovascular disease.
@en
Myeloperoxidase and cardiovascular disease.
@nl
P1476
Myeloperoxidase and cardiovascular disease
@en
P2093
Stanley L Hazen
P304
P356
10.1161/01.ATV.0000163262.83456.6D
P407
P577
2005-03-24T00:00:00Z